Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
- 13 September 2024
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 21 (11) , 818-832
Abstract
HER2-targeted therapies for patients with HER2+ breast cancer are rapidly evolving, offering a range of more complex and personalized treatment options. Currently, an array of anti-HER2 monoclonal antibodies, tyrosine kinase inhibitors and antibody–drug conjugates are administered, sometimes alongside chemotherapy or endocrine therapy, both in curative and palliative contexts. However, the heterogeneous nature of HER2+ breast cancer demands a deeper understanding of disease biology and its role in responsiveness to novel HER2-targeted agents, as well as non-HER2-targeted therapies, in order to optimize patient outcomes. In this Review, we revisit the mechanisms of action of HER2-targeted agents, examine the evidence supporting the use of dual HER2 blockade in patients with HER2-amplified tumours, and explore the role of biomarkers in guiding future treatment strategies. We also discuss potential implications for the future treatment of patients with HER2+ breast cancer.Keywords
This publication has 158 references indexed in Scilit:
- Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast CancerJAMA Oncology, 2024
- Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast CancerJAMA Oncology, 2023
- Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and PertuzumabJAMA Oncology, 2023
- Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without PertuzumabJAMA Oncology, 2023
- Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast CancerJAMA Oncology, 2023
- Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain MetastasesJAMA Oncology, 2022
- Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast CancerJAMA Oncology, 2022
- Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of DualERBB2Blockade in Patients WithERBB2-Positive Breast CancerJAMA Oncology, 2021
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast CancerJAMA Oncology, 2021
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and TrastuzumabJAMA Oncology, 2015